Adipotide
An experimental fat-targeting peptide that selectively destroys blood vessels feeding white adipose tissue. Produced dramatic fat loss in primate studies but was discontinued due to kidney toxicity.
What is Adipotide?
Adipotide (FTPP) is a synthetic chimeric peptide composed of two functional domains: a cyclic targeting motif (CKGGRAKDC) that selectively binds prohibitin on endothelial cells in white adipose tissue vasculature, fused to D(KLAKLAK)2, a peptidomimetic sequence that disrupts mitochondrial membranes upon internalization. Rather than acting on fat cells directly, adipotide destroys the blood vessels that supply fat tissue, depriving adipocytes of oxygen and nutrients. It produced striking fat loss results in obese primates — up to 39% body fat reduction — but clinical development was discontinued after dose-dependent, reversible kidney toxicity was observed.
What Adipotide Is Investigated For
Adipotide was investigated as a targeted fat-loss agent that destroys the blood vessels supplying white adipose tissue, causing secondary adipocyte death from ischemia. The strongest evidence is from a single landmark primate study (Science Translational Medicine, 2011) showing up to 38.7% reduction in total body fat and 48.5% improvement in insulin sensitivity over 28 days in obese rhesus macaques — genuinely dramatic preclinical results. The same study, however, documented dose-dependent renal proximal tubular injury at the therapeutic doses, caused by prohibitin expression in kidney tubules, and clinical development was discontinued because the therapeutic window between fat loss and nephrotoxicity was too narrow for safe translation. Adipotide has never been tested in humans, has no Investigational New Drug status, and has not progressed in over a decade. Its presence in grey-market research-chemical channels is notable specifically because the kidney toxicity is mechanistically intrinsic to the molecule, not a formulation issue that can be engineered away.
History & Discovery
Adipotide was developed in the laboratories of Wadih Arap and Renata Pasqualini at the University of Texas MD Anderson Cancer Center, building on their earlier discovery that prohibitin is selectively expressed on the endothelial cells lining blood vessels of white adipose tissue. The molecule was designed as a chimeric peptidomimetic with two functional halves: a cyclic targeting motif (CKGGRAKDC) identified from in vivo phage-display screens that binds prohibitin, and a synthetic D-amino-acid sequence D(KLAKLAK)2 that disrupts mitochondrial membranes upon receptor-mediated internalization. The premise was direct: rather than reducing food intake or modulating metabolism, eliminate the vasculature feeding white adipose tissue and let the fat cells die from ischemia. The landmark 2011 Science Translational Medicine paper reported that 28 days of subcutaneous adipotide produced 11% body weight loss and a 39% reduction in body fat in obese rhesus macaques, with substantial improvement in insulin resistance. The same paper, however, also documented dose-dependent renal proximal tubule injury — caused by prohibitin expression in kidney tubular cells, an off-target site of the targeting motif. The therapeutic window between fat loss and nephrotoxicity proved too narrow for safe clinical translation. Adipotide has never been tested in humans and no clinical trial has ever been initiated.
How It Works
Adipotide works like a guided missile for fat tissue. One part of the peptide finds and locks onto blood vessels that specifically feed fat deposits. The other part punches holes in those blood vessel cells, destroying them. Without blood supply, the fat tissue starves and shrinks. The problem is that the "missile" can also hit kidney blood vessels, causing damage.
Adipotide is a chimeric peptide with two functional domains. The N-terminal cyclic motif CKGGRAKDC binds to prohibitin, a receptor selectively expressed on the surface of endothelial cells in white adipose tissue vasculature. Upon receptor-mediated internalization, the C-terminal D(KLAKLAK)2 domain — a synthetic sequence composed entirely of D-amino acids for protease resistance — disrupts mitochondrial membranes, triggering apoptosis in the target endothelial cells. The resulting vascular destruction deprives white adipose tissue of blood supply, leading to adipocyte death and resorption. In obese rhesus macaques, this mechanism produced a 38.7% reduction in total body fat (DEXA-confirmed) and a 36.2% decrease in insulin AUC over 28 days at 0.43 mg/kg/day. The kidney toxicity results from prohibitin expression in renal proximal tubular cells, where adipotide causes off-target tubular degeneration and single-cell necrosis.
Evidence Snapshot
Human Clinical Evidence
None. Adipotide has never been tested in human clinical trials. Development was discontinued at the preclinical stage due to kidney toxicity in primates.
Animal / Preclinical
Strong within primates. A study in 39 rhesus macaques, 2 baboons, and 52 cynomolgus monkeys demonstrated dose-dependent weight loss (up to 20.4% body weight), 38.7% total body fat reduction, and significant improvement in insulin resistance (48.5% reduction in insulinogenic index). MRI and DEXA confirmed white adipose tissue volume decreases. However, dose-dependent renal tubular injury was observed at therapeutic doses, reversible within 28 days post-treatment.
Mechanistic Rationale
Strong. The vascular targeting mechanism is well-characterized: prohibitin binding, endothelial cell internalization, mitochondrial membrane disruption, and subsequent adipose tissue ischemia. The off-target kidney toxicity is also mechanistically understood (prohibitin expression in renal tubules). Published in Science Translational Medicine.
Research Gaps & Open Questions
What the current literature has not yet settled about Adipotide:
- 01Whether a safer dosing regimen (lower dose, intermittent dosing, alternate route) could preserve fat-loss efficacy while avoiding nephrotoxicity has not been formally explored, and the discontinuation of the program means it likely never will be in this molecule's current form.
- 02Whether the fat loss observed in primates would be durable in humans is unknown — no human exposure has ever occurred.
- 03Modified targeting motifs that retain prohibitin binding selectivity for adipose vasculature while sparing renal tubular endothelium would address the central liability but have not been published as a successor program.
- 04Long-term effects on adipose tissue regeneration and metabolic recovery after vasculature destruction are not well characterized.
- 05Effects on brown adipose tissue (which does not strongly express the same prohibitin pattern) versus white adipose tissue have not been formally distinguished in vivo.
- 06Real-world adverse event data from grey-market human use are anecdotal, unverified, and dominated by case reports of acute kidney injury that fit the primate toxicology profile.
Forms & Administration
Adipotide was administered via daily subcutaneous injection in primate studies at 0.43 mg/kg. It is not approved for human use and is not available through legitimate medical channels. Due to documented kidney toxicity, this peptide should not be self-administered under any circumstances.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
There is no human dose. The published preclinical regimen in obese rhesus macaques was 0.43 mg/kg/day subcutaneously for 28 days. Material sold under the adipotide name in research-chemical channels typically carries vague dosing recommendations that have no clinical evidence base whatsoever — these dosing claims should be regarded as inventions, not protocols.
Frequency
Daily subcutaneous injection in the published primate studies. Any human dosing claim is fabricated.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
The published primate protocol was 28 days, after which the dose-dependent renal injury was the limiting factor. Recovery of renal function occurred within 28 days of stopping treatment, but the injury was real and dose-dependent. There is no concept of a 'safe cycle' in humans because no safe human dose has been established and no human exposure has occurred in regulated trials.
Protocol Notes
Adipotide is not a clinical drug. It exists in the research-chemical and grey-market peptide space because the primate fat-loss data is striking, but the same primate data documented kidney damage that derailed clinical development. Anyone considering adipotide should understand that the renal toxicity is not theoretical or speculative — it was directly observed in non-human primate studies at the doses that produced the fat loss. The mechanism (prohibitin expression in renal proximal tubule cells, leading to tubular degeneration and necrosis) is intrinsic to the molecule's design, not a fixable formulation issue. There is no antidote, no monitoring protocol that would catch damage before it occurred, and no safer dosing regimen has been characterized.
Adipotide is not approved by any regulatory authority for human use, has never been tested in human clinical trials, and demonstrated dose-dependent renal toxicity in primate studies at therapeutic doses. Self-administration is dangerous and is strongly discouraged.
Timeline of Effects
Onset
In the rhesus macaque study, fat loss became measurable within the 28-day dosing window via DEXA imaging. Kidney injury markers (elevated serum creatinine, glucosuria, proteinuria) emerged in the same window, dose-dependent and concurrent with the therapeutic effect.
Peak Effect
The published primate data documented up to 11% body weight loss and 38.7% body fat reduction over 28 days at 0.43 mg/kg/day. Whether longer dosing would produce greater fat loss before causing irreversible kidney injury was not tested because development was discontinued.
After Discontinuation
In primates, the renal injury was reversible within 28 days of stopping adipotide. The fat loss was characterized as durable in the published 28-day post-treatment follow-up, though longer-term durability was not assessed and the underlying mechanism (vasculature destruction with subsequent adipocyte loss) would predict gradual revascularization over months. No human discontinuation data exist because no human exposure has occurred.
Common Questions
Who Adipotide Is NOT For
- •Existing kidney disease or impaired renal function — the documented dose-dependent nephrotoxicity makes adipotide affirmatively dangerous in this population, where the renal reserve to absorb tubular injury is already reduced.
- •Diabetes with established or developing nephropathy — same renal-reserve concern applies.
- •Pregnancy and breastfeeding — no human safety data, and the mechanism (vasculature destruction) is the kind of pharmacology incompatible with fetal development.
- •Pediatric use — entirely contraindicated; no pediatric data and no plausible justification for risk in a developing population.
- •Concurrent use of other nephrotoxic agents (NSAIDs at therapeutic doses, aminoglycoside antibiotics, contrast agents, certain chemotherapy) — additive renal injury risk.
- •Hypovolemia or dehydration — increases vulnerability to renal tubular injury.
- •Effectively, adipotide should be regarded as contraindicated in all human populations until and unless a regulated clinical trial establishes a safe and effective dosing window — which has not happened in over a decade since the primate data were published.
Drug & Supplement Interactions
Documented drug-interaction data for adipotide in humans are nonexistent because the molecule has never been administered to humans in any regulated context. The most clinically relevant theoretical interaction is with other nephrotoxic agents — NSAIDs (especially at higher doses), aminoglycoside antibiotics, IV contrast agents, certain chemotherapy regimens, and other proximal-tubule-active drugs — which would compound the dose-dependent renal injury observed in primates. Diuretic use during dehydration could similarly increase tubular vulnerability. The vascular-targeting mechanism could in principle interact with anti-angiogenic oncology therapies (bevacizumab, VEGF tyrosine kinase inhibitors) in unpredictable ways, though the specific tissue-targeting profile (white adipose tissue plus off-target renal tubular endothelium) does not overlap closely with tumor angiogenesis. Beyond these theoretical concerns, the absence of human pharmacology data means any drug-interaction discussion is fundamentally speculative.
Safety Profile
Common Side Effects
Cautions
- • Clinical development was discontinued due to kidney toxicity
- • Narrow therapeutic window between effective and toxic doses
- • Not FDA-approved and not in clinical trials
- • Gray market sources have unknown purity and composition
- • Should NOT be self-administered — kidney damage risk is real and documented
What We Don't Know
No human clinical data exists. The kidney toxicity observed in primates was reversible within 28 days, but long-term effects of repeated exposure are unknown. Whether a safer dosing regimen could preserve efficacy while avoiding renal damage has not been explored.
Legal Status
United States
Adipotide is not FDA-approved, has no Investigational New Drug application status, and is not in any active clinical trial. Material sold under the adipotide name through research-chemical suppliers is sold for laboratory research use only and is not authorized for human use. The clinical-development discontinuation following the primate toxicity data has not been reversed.
International
No regulatory authority in any jurisdiction has approved adipotide or has an active clinical trial program. The molecule is uniformly investigational-discontinued worldwide.
Sports & Competition
Adipotide is not listed by name on the WADA Prohibited List, but it falls under WADA's S0 category (substances not approved by any government regulatory health authority for human therapeutic use). Athletes subject to WADA, USADA, or equivalent codes should treat it as prohibited in and out of competition. Beyond the anti-doping classification, the documented nephrotoxicity makes adipotide a particularly ill-advised choice for athletes who depend on intact renal function.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Adipotide is a clinical drug being studied for obesity.
Reality
Adipotide has never been tested in humans, has no Investigational New Drug status, and is not in any active clinical trial program. Clinical development was discontinued at the preclinical primate stage in 2011 due to dose-dependent kidney toxicity. It exists today only in research-chemical channels.
Myth
The kidney toxicity in primates was reversible, so it is fine to use adipotide as long as you stop in time.
Reality
The primate renal injury was reversible within 28 days in controlled laboratory conditions with continuous monitoring. Real-world human use lacks the monitoring infrastructure that would catch tubular injury before it became significant, and reversibility cannot be assumed for higher doses, longer exposures, or patients with reduced renal reserve. The mechanism (prohibitin expression in renal tubule cells) is intrinsic and not reformulatable.
Myth
Adipotide selectively kills only fat cells.
Reality
Adipotide does not target fat cells (adipocytes) at all. It targets the endothelial cells lining the blood vessels that feed white adipose tissue. The fat cells die secondarily from ischemia. The same prohibitin receptor that the targeting motif recognizes is also expressed on renal tubular cells, which is the source of the off-target toxicity. The selectivity is real but imperfect, and the imperfection is what derailed clinical development.
Myth
Because adipotide produces real fat loss, the risks are worth it for cosmetic or athletic goals.
Reality
The risk in question is acute kidney injury, including tubular degeneration and necrosis, in healthy people taking an unstudied molecule under no medical supervision. There is no aesthetic or athletic outcome for which this risk is reasonable, and there is no monitoring protocol that reliably catches damage before it occurs. The published data establish what adipotide does to kidneys at doses that produce fat loss.
Published Research
3 studiesRapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium.
A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys.
Peptide Designed to Elicit Apoptosis in Adipose Tissue Endothelium Reduces Food Intake and Body Weight.
Quick Facts
- Class
- Proapoptotic Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Use Caution
- Updated
- Apr 2026
- Citations
- 3PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.